Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Adam Knott, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine Piccart, Jose Baselga

Open source

DOI: 10.1056/nejmoa1703643
Published: 2017-07-13
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
cautionRetraction Watch correction: 1 correction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1703643,
  title = {Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer},
  author = {Gunter von Minckwitz and Marion Procter and Evandro de Azambuja and Dimitrios Zardavas and Mark Benyunes and Giuseppe Viale and Thomas Suter and Amal Arahmani and Nathalie Rouchet and Emma Clark and Adam Knott and Istvan Lang and Christelle Levy and Denise A. Yardley and Jose Bines and Richard D. Gelber and Martine Piccart and Jose Baselga},
  year = {2017},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa1703643},
  url = {https://doi.org/10.1056/nejmoa1703643}
}

RIS

TY  - JOUR
TI  - Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
AU  - Gunter von Minckwitz
AU  - Marion Procter
AU  - Evandro de Azambuja
AU  - Dimitrios Zardavas
AU  - Mark Benyunes
AU  - Giuseppe Viale
AU  - Thomas Suter
AU  - Amal Arahmani
AU  - Nathalie Rouchet
AU  - Emma Clark
AU  - Adam Knott
AU  - Istvan Lang
AU  - Christelle Levy
AU  - Denise A. Yardley
AU  - Jose Bines
AU  - Richard D. Gelber
AU  - Martine Piccart
AU  - Jose Baselga
PY  - 2017
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa1703643
UR  - https://doi.org/10.1056/nejmoa1703643
ER  -

APA

Minckwitz, G. V., Procter, M., Azambuja, E. D., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M., & Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1703643

Source records

crossref · retrieved 2026-09-24T20:59:46.010Z